Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

One of the companies mentioned in the letter is Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals Inc. ...

Shares of Regeneron Pharmaceuticals Inc. slipped 3.03% to $545.94 Monday, on what proved to be an all-around poor trading ...

Amid a solid earnings picture for the second quarter, many US-listed companies are beating their estimates. Combining the ...

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

Harrow's Q2 results show promise, but high debt, market challenges, and execution risks loom. Read here for strategies to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

Cary Street Partners Financial LLC dramatically reduced its stake in Regeneron Pharmaceuticals. The firm now holds a mere 255 ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- ...